The VesiVax® System: Vaccine development made easy

August 12, 2016

Dr. Qizhi Cathy Yao, professor of surgery, molecular virology and microbiology, and pathology & immunology at Baylor College of Medicine, has been awarded a National Institutes of Health grant to fund a collaborative project with Molecular Express, Inc. The project is based on their virus-like particle (VLP) vaccine strategy.

Virus-like particles have the unique property of inducing strong immune responses but they lack the infectious capacities of the original virus. In preclinical studies, VLPs formed by structural proteins are highly immunogenic. When VLPs are conjugated with VesiVax® formulations containing toll-like receptor agonists, strong humoral and cellular immune responses against various diseases can be generated.

Previously, Yao's lab studied the basic mechanisms of VLP-induced immune responses and other factors that affect these responses. For example, they found that VLP vaccines activate conventional B2 cells and promote B cell differentiation to IgG2a-producing plasma cells. They also found that VLP vaccines travel to the lymph nodes upon immunization and can be directly visualized with optical imaging techniques. In addition, intradermal immunization generates improved responses and might be a preferable delivery route for viral and cancer immunotherapeutic studies involving VLPs.

In this new study, Yao will use the "VesiVax® System: Vaccine Development Made Easy" to develop better adjuvants for many different diseases, including pancreatic cancer and Chagas disease.
-end-
This research was supported by the National Institute of Allergy and Infectious Diseases of the National Institutes of Health under award number R44AI094770.

Baylor College of Medicine

Related Immunization Articles from Brightsurf:

Safety of HPV vaccines in males
A new analysis published in the British Journal of Clinical Pharmacology shows that HPV vaccines are safe and well tolerated in the male population, and the side effects that may occur after immunization are similar in both sexes.

Key populations for early COVID-19 immunization in Canada
Canada's National Advisory Committee on Immunization (NACI) recommends vaccinating key populations, such as people at risk of severe illness or death, those at risk of transmitting the virus and essential workers, during the initial rollout of a COVID-19 vaccine in Canada.

Malaria vaccine trial samples reveal immune benchmarks for achieving protection
By studying samples from two independent clinical trials of malaria vaccines, Gemma Moncunill and colleagues have linked signatures in the immune system to better vaccine protection from the disease in children and adults.

Passive immunization may slow down SARS-CoV-2 and boost immunity in patients, buying time
The worldwide COVID-19 pandemic has infected more than 4 million people and killed close to 280,000.1 Finding a vaccine has become a global public health priority.

Study results will inform immunization programs globally
The results of the B Part of It study -- the largest meningococcal B herd immunity study ever conducted -- are published today in the New England Journal of Medicine.

Changed route of immunization dramatically improves efficacy of TB vaccine
Tuberculosis (TB), an ancient disease, is the leading infectious cause of death globally, yet the world's only licensed TB vaccine, Bacille Calmette-Guerin (BCG), was developed a century ago.

HPV immunization program cuts pre-cancer rates by more than half
A school-based human papillomavirus (HPV) immunization program in British Columbia, Canada, is dramatically reducing rates of cervical pre-cancer in B.C. women, according to a new study.

Vaccine report calls for innovative transformation strategies to increase influenza immunization rates in underserved communities
Sustainable Healthy Communities announced the publication of a summary report in Vaccine, the leading peer-reviewed journal focused on immunization science, urging health systems, providers and community stakeholders to implement evidence-based strategies to address racial disparities in influenza immunization.

Advantages of DNA immunization platform for eliciting mAbs in multiple species
Researchers have taken advantage of the benefits of DNA immunization over traditional protein-based immunization to elicit monoclonal antibodies (mAbs) against challenging targets in three species -- mouse, rabbit, and human models.

Timing of third-trimester maternal Tdap immunization associated with levels of whooping cough antibodies in newborns
Risk of whooping cough (pertussis) is highest in infants too young to have completed their primary immunization series (6 months old or younger) and they are at highest risk of developing life-threatening complications.

Read More: Immunization News and Immunization Current Events
Brightsurf.com is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to Amazon.com.